Bioscience Animal Health Valuation

Q: What is the Fair Price of BIS-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

BIS-R (THB3.4) is trading above our estimate of [[fair value]] (THB3.03)

Is BIS-R undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIS-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BIS-R (THB3.4) is trading above our estimate of fair value (THB3.03)

Significantly Below Fair Value: BIS-R is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIS-R?

Key metric: As BIS-R is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BIS-R. This is calculated by dividing BIS-R's market cap by their current earnings.
What is BIS-R's PE Ratio?
PE Ratio	17x
Earnings	฿62.67m
Market Cap	฿1.07b

BIS-R key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.4x
Enterprise Value/EBITDA	9.2x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does BIS-R's PE Ratio compare to its peers?

The above table shows the PE ratio for BIS-R vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	19.1x
SEI SEI Medical	21.4x	25.0%	฿846.6m
WINMED Winnergy Medical	26.8x	n/a	฿744.0m
SMD SaintMed	18.7x	n/a	฿1.0b
BIZ Business Alignment	9.4x	n/a	฿2.1b
BIS-R Bioscience Animal Health	17x	n/a	฿1.1b

Price-To-Earnings vs Peers: BIS-R is good value based on its Price-To-Earnings Ratio (17x) compared to the peer average (19.1x).

Price to Earnings Ratio vs Industry

How does BIS-R's PE Ratio compare vs other companies in the TH Healthcare Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: BIS-R is good value based on its Price-To-Earnings Ratio (17x) compared to the TH Healthcare industry average (21.5x).

Price to Earnings Ratio vs Fair Ratio

What is BIS-R's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIS-R PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	17x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BIS-R's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Ramkhamhaeng Hospital

฿27.8b

Operates a private hospital that provides medical services in Thailand.

RAM-R

฿23.20

-35.6%

Patrangsit Healthcare Group

฿3.6b

Operates hospitals in Thailand.

PHG-F

฿9.45

n/a

Nonthavej Hospital

฿5.0b

Operates as a hospital in Thailand.

NTV

฿31.50

-0.8%

-14.9%